Data compiled by Redley Lamar · ChainSifter Intelligence
6Suppliers
3Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
Medicus Pharma Ltd. (MDCX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
13Total relationships
5Distinct source URLs
10High confidence
0.840Average confidence
2026-07-01Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Medicus Pharma Ltd. Suppliers
Ticker
Name
Confidence
Evidence
UNIVERSITY-OF-PITTSBURGH
UNIVERSITY-OF-PITTSBURGH
92%
SkinJect entered into an exclusive license agreement with the University of Pittsburgh
YA-II-PN-LTD
YA-II-PN-LTD
92%
The Company may cause Yorkville to purchase additional Common Shares under the SEPA from time to time, subject to the satisfaction or waiver of the conditions and limitations set forth in the SEPA.
YORKVILLE
YORKVILLE
92%
The Company has entered into a standby equity purchase agreement dated February 10, 2025 (the "SEPA") with Yorkville, an investment fund managed by Yorkville Advisors Global, LP.
MAXIM-GROUP-LLC
MAXIM-GROUP-LLC
90%
Medicus Pharma Ltd. (the "Company") entered into an Equity Distribution Agreement (the "Agreement") with Maxim Group LLC ("Maxim") and Yorkville Securities, LLC ("Yorkville Securities", and together …
YA-II-PN-LT
YA-II-PN-LT
90%
The Company has entered into a standby equity purchase agreement dated February 10, 2025 (the "SEPA") with YA II PN, Lt
YORKVILLE-SECURITIES-LLC
YORKVILLE-SECURITIES-LLC
90%
Medicus Pharma Ltd. (the "Company") entered into an Equity Distribution Agreement (the "Agreement") with Maxim Group LLC ("Maxim") and Yorkville Securities, LLC ("Yorkville Securities", and together …
Medicus Pharma Ltd. Customers
Ticker
Name
Confidence
Evidence
ANTEV-LIMITED
ANTEV-LIMITED
62%
470-50 states that if the discounted cash flows under the terms of the new debt instrument are at least ten percent different from the discounted cash flows under the terms of the original instrument…
F-28-MEDICUS-PHARMA-LTD
F-28-MEDICUS-PHARMA-LTD
62%
. Interest will accrue on the outstanding principal amount of the debenture at an annual rate of 8 %, subject to a potential increase to 18 % per annum upon the occurrence of certain events of defaul…
F-29-MEDICUS-PHARMA-LTD
F-29-MEDICUS-PHARMA-LTD
62%
. Interest will accrue on the outstanding principal amount of the debenture at an annual rate of 8 %, subject to a potential increase to 18 % per annum upon the occurrence of certain events of defaul…
Medicus Pharma Ltd. Debt Obligations
Instrument
Description
Confidence
Evidence
MDCX-DEBT-10910
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2025-12-31.
MDCX-DEBT-10909
Warrants outstanding: 4.64
90%
xbrl warrant detail from xbrl 2025-12-31.
MDCX-DEBT
Debt stack $2.5M
90%
Market cache reports total debt of $2.5M.
Medicus Pharma Ltd. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Medicus Pharma Ltd..
Medicus Pharma Ltd. Ownership
Holder
Name
Confidence
Evidence
MDCX-OWNER-ARMISTICE-CAPITAL-LLC
Armistice Capital, LLC
90%
13F overlay lists Armistice Capital, LLC as top holder; 10 tracked holders.
